Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 430-444

  Cisbani, G ^a,d   Drouin Ouellet, J ^b   Gibrat, C ^a   Saint Pierre, M ^a   Lagace M ^a   Badrinarayanan, S ^a   Lavallee Bourget M H ^a   Charest, J ^c   Chabrat, A ^c   Boivin, L ^a   Lebel, M ^a   Bousquet, M ^a   Levesque M ^c,d   Cicchetti, F ^a,d  

^a Université Laval   (Canada)

^b LUND UNIVERSITY   (Sweden)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

6 OHDA; Disease modifying; Neuroprotection; Neurorescue

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYSTAMINE; DOPAMINE TRANSPORTER; MERCAPTAMINE; NUCLEAR RECEPTOR RELATED FACTOR 1; OXIDOPAMINE; RASAGILINE; ANTIPARKINSON AGENT; INDAN DERIVATIVE; LIPOPOLYSACCHARIDE; NEUROPROTECTIVE AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; EX VIVO STUDY; EXPLANT; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOTOR DYSFUNCTION; MOUSE; MOUSE MODEL; NERVE CELL NECROSIS; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; WESTERN BLOTTING; ANIMAL; ASTROCYTE; C57BL MOUSE; CELL CULTURE; CELL LINE; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; MALE; NEURITE; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; ASTROCYTES; CELL LINE; CELLS, CULTURED; CORPUS STRIATUM; CYSTAMINE; CYSTEAMINE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; INDANS; LIPOPOLYSACCHARIDES; MALE; MICE, INBRED C57BL; NEURITES; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS;

EID: 84939627579     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.07.012     Document Type: Article

References (71)

1. Abu-Raya S., Blaugrund E., Trembovler V., Shilderman-Bloch E., Shohami E., Lazarovici P. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J. Neurosci. Res. 1999, 58:456-463.
2. Allen Allen Brain Atlas. Seattle (WA): Allen Institute for Brain Science Available from:. http://www.brain-map.org.
3. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Hoglinger G.U., Oertel W.H., Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp. Neurol. 2008, 210:182-193.
4. Björklund A., Kordower J.H. Cell therapy for Parkinson's disease: what next?. Mov. Disord. 2013, 28:110-115.
5. Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?. CNS Drug Rev. 2005, 11:183-194.
6. Blandini F., Armentero M.T., Fancellu R., Blaugrund E., Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. 2004, 187:455-459.
7. Blume S.R., Cass D.K., Tseng K.Y. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism. Exp. Neurol. 2009, 219:208-211.
8. Borrell-Pagès M., Canals J.M., Cordelières F.P., Parker J.A., Pineda J.R., Grange G., Bryson E.A., Guillermier M., Hirsch E., Hantraye P., Cheetham M.E., Néri C., Alberch J., Brouillet E., Saudou F., Humbert S. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 2006, 116:1410-1424.
9. Bousquet M., Saint-Pierre M., Julien C., Salem N., Cicchetti F., Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J. 2008, 22:1213-1225.
10. Bousquet M., Gibrat C., Saint-Pierre M., Julien C., Calon F., Cicchetti F. Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33:1401-1408.
11. Bousquet M., Gibrat C., Ouellet M., Rouillard C., Calon F., Cicchetti F. Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J. Neurochem. 2010, 114:1651-1658.
12. Bousquet M., Gue K., Emond V., Julien P., Kang J.X., Cicchetti F., Calon F. Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease. J. Lipid Res. 2011, 52:263-271.
13. Bousquet M., St-Amour I., Vandal M., Julien P., Cicchetti F., Calon F. High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. Neurobiol. Dis. 2012, 45:529-538.
14. Dedeoglu A., Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., Matson W.R., Cooper A.J., Ratan R.R., Beal M.F., Hersch S.M., Ferrante R.J. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 2002, 22:8942-8950.
15. Drouin-Ouellet J., Brownell A.-L., Saint-Pierre M., Fasano C., Emond V., Trudeau L.-E., Lévesque D., Cicchetti F. Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. Glia 2011, 59:188-199.
16. Drouin-Ouellet J., Gibrat C., Bousquet M., Calon F., Kriz J., Cicchetti F. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. J. Neuroinflammation 2011, 8:137.
17. Dubinsky R., Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov. Disord. 2006, 21:530-533.
18. Fox J.H., Barber D.S., Singh B., Zucker B., Swindell M.K., Norflus F., Buzescu R., Chopra R., Ferrante R.J., Kazantsev A., Hersch S.M. Cystamine increases l-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 2004, 91:413-422.
19. Gaines K.D., Hinson V.K. Adjunctive therapy in Parkinson's disease: the role of rasagiline. Neuropsychiatr. Dis. Treat. 2012, 8:285-294.
20. Galea E., Feinstein D.L., Reis D.J. Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:10945-10949.
21. García Navia J.T., Burguillos M.A., Ramón-Cueto A., Machado A., Cano J., Venero J.L. Regional-specific regulation of BDNF and trkB correlates with nigral dopaminergic cell sprouting following unilateral nigrostriatal axotomy. J. Neurosci. Res. 2008, 86:2016-2027.
22. Gibrat C., Cicchetti F. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:380-389.
23. Gibrat C., Saint-Pierre M., Bousquet M., Levesque D., Rouillard C., Cicchetti F. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J. Neurochem. 2009, 109:1469-1482.
24. Gibrat C., Bousquet M., Saint-Pierre M., Levesque D., Calon F., Rouillard C., Cicchetti F. Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34:193-203.
25. Grealish S., Diguet E., Kirkeby A., Mattsson B., Heuer A., Bramoulle Y., Van Camp N., Perrier A.L., Hantraye P., Björklund A., Parmar M. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease. Cell Stem Cell 2014, 15:653-665.
26. Hanrott K., Gudmunsen L., O'Neill M.J., Wonnacott S. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 2006, 281:5373-5382.
27. Hauser R.A., Lew M.F., Hurtig H.I., Ondo W.G., Wojcieszek J., Fitzer-Attas C.J., TEMPO Open-label Study Group Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov. Disord. 2009, 24:564-573.
28. Hirsch E.C., Vyas S., Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18:S210-S212.
29. Jókay I., Kelemenics K., Gyuris A., Minárovits J. S-methylthio-cysteine and cystamine are potent stimulators of thiol production and glutathione synthesis. Life Sci. 1998, 62:L27-L33.
30. Junn E., Ronchetti R.D., Quezado M.M., Kim S.-Y., Mouradian M.M. Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2047-2052.
31. Karpuj M.V., Becher M.W., Steinman L. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem. Int. 2002, 40:31-36.
32. Koprowski H., Zheng Y.M., Heber-Katz E., Fraser N., Rorke L., Fu Z.F., Hanlon C., Dietzschold B. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3024-3027.
33. Korchounov A., Winter Y., Rössy W. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin. Neuropharmacol. 2012, 35:121-124.
34. Kupsch A., Sautter J., Götz M.E., Breithaupt W., Schwarz J., Youdim M.B., Riederer P., Gerlach M., Oertel W.H. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm. 2001, 108:985-1009.
35. la Fuente-Fernandez de R., Schulzer M., Mak E., Sossi V. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. Parkinsonism Relat. Disord. 2010, 16:365-369.
36. L'Episcopo F., Tirolo C., Caniglia S., Testa N., Serra P.A., Impagnatiello F., Morale M.C., Marchetti B. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neuroinflammation 2010, 7:83.
37. Lesort M., Lee M., Tucholski J., Johnson G.V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 2003, 278:3825-3830.
38. Lorand L., Conrad S.M. Transglutaminases. Mol. Cell. Biochem. 1984, 58:9-35.
39. Maruyama W., Youdim M.B., Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann. N. Y. Acad. Sci. 2001, 939:320-329.
40. Maruyama W., Nitta A., Shamoto-Nagai M., Hirata Y., Akao Y., Yodim M., Furukawa S., Nabeshima T., Naoi M. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem. Int. 2004, 44:393-400.
41. Metz G.A., Whishaw I.Q. Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance. Neuroscience 2002, 111:325-336.
42. Michaud J.-P., Richard K.L., Rivest S. Hematopoietic MyD88-adaptor protein acts as a natural defense mechanism for cognitive deficits in Alzheimer's disease. Stem Cell Rev. 2012, 8:898-904.
43. Mínguez-Mínguez S., Solís-García Del Pozo J., Jordán J. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. Pharmacol. Res. 2013, 74:78-86.
44. Moore A.E., Cicchetti F., Hennen J., Isacson O. Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat. Exp. Neurol. 2001, 172:363-376.
45. Mortimer D., Fothergill T., Pujic Z., Richards L.J., Goodhill G.J. Growth cone chemotaxis. Trends Neurosci. 2008, 31:90-98.
46. Murphy S. Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia 2000, 29:1-13.
47. NPF Statement About Halting of Creatine Study [Internet] Parkinson.org; 2013. [cited 2015 Jan 30] Available from:. http://www.parkinson.org/About-Us/Press-Room/Press-Releases/2013/September/NPF-Statement-About-Halting-of-Creatine-Study.
48. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
49. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., Langston W., Melamed E., Poewe W., Stocchi F., Tolosa E., ADAGIO Study Investigators A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 2009, 361:1268-1278.
50. Ostergaard K., Jones S.A., Hyman C., Zimmer J. Effects of donor age and brain-derived neurotrophic factor on the survival of dopaminergic neurons and axonal growth in postnatal rat nigrostriatal cocultures. Exp. Neurol. 1996, 142:340-350.
51. Ousman S.S., Kubes P. Immune surveillance in the central nervous system. Nat. Neurosci. 2012, 15:1096-1101.
52. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 2002, 59:1937-1943.
53. Parkinson Study Group QE3 Investigators, Beal M.F., Oakes D., Shoulson I., Henchcliffe C., Galpern W.R., Haas R., Juncos J.L., Nutt J.G., Voss T.S., Ravina B., Shults C.M., Helles K., Snively V., Lew M.F., Griebner B., Watts A., Gao S., Pourcher E., Bond L., Kompoliti K., Agarwal P., Sia C., Jog M., Cole L., Sultana M., Kurlan R., Richard I., Deeley C., Waters C.H., Figueroa A., Arkun A., Brodsky M., Ondo W.G., Hunter C.B., Jimenez-Shahed J., Palao A., Miyasaki J.M., So J., Tetrud J., Reys L., Smith K., Singer C., Blenke A., Russell D.S., Cotto C., Friedman J.H., Lannon M., Zhang L., Drasby E., Kumar R., Subramanian T., Ford D.S., Grimes D.A., Cote D., Conway J., Siderowf A.D., Evatt M.L., Sommerfeld B., Lieberman A.N., Okun M.S., Rodriguez R.L., Merritt S., Swartz C.L., Martin W.R.W., King P., Stover N., Guthrie S., Watts R.L., Ahmed A., Fernandez H.H., Winters A., Mari Z., Dawson T.M., Dunlop B., Feigin A.S., Shannon B., Nirenberg M.J., Ogg M., Ellias S.A., Thomas C.-A., Frei K., Bodis-Wollner I., Glazman S., Mayer T., Hauser R.A., Pahwa R., Langhammer A., Ranawaya R., Derwent L., Sethi K.D., Farrow B., Prakash R., Litvan I., Robinson A., Sahay A., Gartner M., Hinson V.K., Markind S., Pelikan M., Perlmutter J.S., Hartlein J., Molho E., Evans S., Adler C.H., Duffy A., Lind M., Elmer L., Davis K., Spears J., Wilson S., Leehey M.A., Hermanowicz N., Niswonger S., Shill H.A., Obradov S., Rajput A., Cowper M., Lessig S., Song D., Fontaine D., Zadikoff C., Williams K., Blindauer K.A., Bergholte J., Propsom C.S., Stacy M.A., Field J., Mihaila D., Chilton M., Uc E.Y., Sieren J., Simon D.K., Kraics L., Silver A., Boyd J.T., Hamill R.W., Ingvoldstad C., Young J., Thomas K., Kostyk S.K., Wojcieszek J., Pfeiffer R.F., Panisset M., Beland M., Reich S.G., Cines M., Zappala N., Rivest J., Zweig R., Lumina L.P., Hilliard C.L., Grill S., Kellermann M., Tuite P., Rolandelli S., Kang U.J., Young J., Rao J., Cook M.M., Severt L., Boyar K. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014, 71:543-552.
54. Paul B.D., Sbodio J.I., Xu R., Vandiver M.S., Cha J.Y., Snowman A.M., Snyder S.H. Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington's disease. Nature 2014, 509:96-100.
55. Poewe W., Mahlknecht P., Jankovic J. Emerging therapies for Parkinson's disease. Curr. Opin. Neurol. 2012, 25:448-459.
56. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., Björklund A., Lindvall O., Piccini P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2010, 2:38ra46.
57. Postuma R.B., Lang A.E., Munhoz R.P., Charland K., Pelletier A., Moscovich M., Filla L., Zanatta D., Rios Romenets S., Altman R., Chuang R., Shah B. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012, 79:651-658.
58. Rascol O., Fitzer-Attas C.J., Hauser R., Jankovic J., Lang A., Langston J.W., Melamed E., Poewe W., Stocchi F., Tolosa E., Eyal E., Weiss Y.M., Olanow C.W. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011, 10:415-423.
59. RP103 for Huntington's Disease [Internet] [cited 2015 Jan 30] Available from:. http://www.raptorpharma.com/pipeline/rp103-dr-cysteamine-for-huntingtons-disease.
60. Saavedra A., Baltazar G., Santos P., Carvalho C.M., Duarte E.P. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol. Dis. 2006, 23:533-542.
61. Schapira A.H. Science, medicine, and the future: Parkinson's disease. BMJ 1999, 318:311-314.
62. Schmidt E.R.E., Morello F., Pasterkamp R.J. Dissection and culture of mouse dopaminergic and striatal explants in three-dimensional collagen matrix assays. J. Vis. Exp. 2012.
63. Smidt M.P., Asbreuk C.H., Cox J.J., Chen H., Johnson R.L., Burbach J.P. A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat. Neurosci. 2000, 3:337-341.
64. Stack E.C., Ferro J.L., Kim J., Del Signore S.J., Goodrich S., Matson S., Hunt B.B., Cormier K., Smith K., Matson W.R., Ryu H., Ferrante R.J. Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim. Biophys. Acta 2008, 1782:151-162.
65. Swanson R.A., Ying W., Kauppinen T.M. Astrocyte influences on ischemic neuronal death. Curr. Mol. Med. 2004, 4:193-205.
66. Tremblay R.G., Sikorska M., Sandhu J.K., Lanthier P., Ribecco-Lutkiewicz M., Bani-Yaghoub M. Differentiation of mouse Neuro 2A cells into dopamine neurons. J. Neurosci. Methods 2010, 186:60-67.
67. van Praag H., Kempermann G., Gage F.H. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat. Neurosci. 1999, 2:266-270.
68. Van Raamsdonk J.M., Murphy Z., Slow E.J., Leavitt B.R., Hayden M.R. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2005, 14:3823-3835.
69. Wang X., Sarkar A., Cicchetti F., Yu M., Zhu A., Jokivarsi K., Saint-Pierre M., Brownell A.L. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J. Neurol. Sci. 2005, 231:57-66.
70. Wang H.-P., Hsu T.-C., Hsu G.-J., Li S.-L., Tzang B.-S. Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/WF1 mice. Eur. J. Pharmacol. 2009, 607:102-106.
71. Yan C.H., Levesque M., Claxton S., Johnson R.L., Ang S.-L. Lmx1a and lmx1b function cooperatively to regulate proliferation, specification, and differentiation of midbrain dopaminergic progenitors. J. Neurosci. 2011, 31:12413-12425.